Equities

Tivic Health Systems Inc

TIVC:NAQ

Tivic Health Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.4097
  • Today's Change0.005 / 1.19%
  • Shares traded107.00
  • 1 Year change-96.28%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tivic Health Systems, Inc. is a commercial-stage health tech company advancing the field of bioelectronic medicine. The Company’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Company’s first commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the U.S. directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.

  • Revenue in USD (TTM)1.13m
  • Net income in USD-7.61m
  • Incorporated2021
  • Employees9.00
  • Location
    Tivic Health Systems Inc25821 Industrial Blvd, Ste 100HAYWARD 94545United StatesUSA
  • Fax+1 (302) 636-5454
  • Websitehttps://tivichealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kelyniam Global Inc517.70k-420.28k1.68m0.00--3.13--3.24-0.0253-0.02530.03120.01790.41357.044.38---33.57---41.79--18.86---81.18--1.26--0.6232---26.47---19.10------
Bone Biologics Corp0.00-6.10m1.75m2.00--0.4398-----23.10-23.100.003.620.00----0.00-114.93-98.31-189.37--------------0.00-------502.76------
VirExit Technologies Inc0.00-1.80m1.99m-----------0.0932-0.1130.00-0.03670.00-------6,103.43-----------------3.66-----100.00--19.08------
Aethlon Medical, Inc.574.25k-12.26m2.14m15.00--0.1448--3.73-5.03-5.030.23622.930.0369----38,283.33-78.62-75.30-92.02-84.98-----2,133.17-1,783.78----0.00--95.2130.86-15.55--106.99--
NanoVibronix Inc2.85m-3.20m2.16m10.00--0.6168--0.7583-1.72-1.721.451.260.5160.368313.64285,000.00-57.98-116.16-101.17-169.3668.9850.47-112.35-570.471.38-13.470.00--203.5948.3331.88---34.02--
Dynatronics Corp33.60m-5.14m2.22m154.00--0.298--0.0662-1.19-1.197.583.041.103.338.31218,173.30-14.35-6.02-19.94-8.3021.3727.33-13.07-4.550.6787-12.560.2188---8.41-8.81-19.84---5.11--
Tivic Health Systems Inc1.13m-7.61m2.53m9.00--0.2804--2.23-11.17-11.171.021.460.21840.923717.31126,000.00-146.51---194.55--30.07---670.99--2.07--0.00---36.09--18.34------
Nu-Med Plus Inc0.00-119.16k2.55m2.00---------0.0014-0.00140.00-0.0020.00----0.00-350.01-447.69---------------22.74--------3.56------
InnerScope Hearing Technologies, Inc.334.45k-7.15m2.67m24.00------8.00-0.0153-0.01530.0002-0.00280.09553.931.71---204.11-27.82---94.5317.7958.17-2,138.50-42.130.0022-0.4232------100.59----233.50--
Tenon Medical Inc3.21m-14.33m2.69m21.00--8.28--0.8356-7.24-7.241.430.97240.41082.787.25153,047.60-183.10---269.43--54.70---445.77--2.35--0.00--323.73--17.63------
Vycor Medical Inc1.44m-425.52k2.94m8.00------2.04-0.0133-0.01350.0425-0.10781.590.66726.81179,572.50-11.22-47.86----89.4889.60-7.04-35.420.0861-0.0247----19.43-0.654246.49---31.77--
Therapeutic Solutions International Inc98.99k-2.17m2.96m3.00--2.37--29.91-0.0007-0.00070.000030.00030.02871.134.4432,996.67-64.51-162.32-169.11--62.8567.79-2,247.41-2,391.850.0333-4.920.373---52.1395.3543.11------
Helius Medical Technologies Inc-100.00bn-100.00bn3.14m26.00--0.5544----------2.24-----------98.37---143.57--37.27---1,580.663.26-------18.176.1437.11------
Invo Bioscience Inc4.25m-7.08m3.43m25.00------0.8068-5.68-5.682.590.00390.34739.5030.72169,953.20-57.87-94.63-128.00-151.4539.9074.91-166.64-343.110.1629-5.860.9965--267.3843.6226.24--87.09--
Data as of May 28 2024. Currency figures normalised to Tivic Health Systems Inc's reporting currency: US Dollar USD

Institutional shareholders

4.59%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202447.98k3.27%
Geode Capital Management LLCas of 31 Mar 202412.98k0.89%
Tower Research Capital LLCas of 31 Mar 20246.16k0.42%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024146.000.01%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202411.000.00%
The Northwestern Mutual Life Insurance Co. (Invt Port)as of 31 Mar 20240.000.00%
L1 Capital Global, Inc.as of 31 Dec 20230.000.00%
UBS Securities LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 01 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.